Form 4 Filing for Thomas John Charles

Thomas John Charles, EVP, General Counsel at Krystal Biotech, Inc., reported a series of transactions on June 25, 2026, related to the company's common stock and stock options. These transactions were executed under a Rule 10b5-1 trading plan, which has now been completed and terminated. The plan involved the acquisition of 1000 shares of common stock at $179.25 per share and the disposal of 1000 shares at $347.27 per share. Additionally, Mr. Charles exercised a stock option to buy 1000 shares of common stock at an exercise price of $179.25, with the option vesting over four years starting February 28, 2026. Following these transactions, Mr. Charles holds 6500 shares of common stock.